BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND STK11, LKB1, 6794, ENSG00000118046, Q15831, PJS AND Prognosis
18 results:

  • 1. Hereditary pancreatic cancer.
    Abe K; Kitago M; Kitagawa Y; Hirasawa A
    Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The Genomic Landscape of
    Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
    Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer].
    Damanakis AI; Gebauer F; Bruns CJ
    Chirurg; 2020 Aug; 91(8):642-649. PubMed ID: 32405728
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
    Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Epidemiology and risk factors of pancreatic cancer.
    Capasso M; Franceschi M; Rodriguez-Castro KI; Crafa P; Cambiè G; Miraglia C; Barchi A; Nouvenne A; Leandro G; Meschi T; De' Angelis GL; Di Mario F
    Acta Biomed; 2018 Dec; 89(9-S):141-146. PubMed ID: 30561407
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Integrated Genomic and Immunophenotypic Classification of pancreatic cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
    Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
    Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
    [No Abstract]    [Full Text] [Related]  

  • 7. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.
    Zheng B; Peng J; Mollayup A; Bakri A; Guo L; Zheng J; Xu H
    Mol Med Rep; 2018 Jan; 17(1):216-224. PubMed ID: 29115420
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma.
    Kumazoe M; Takai M; Hiroi S; Takeuchi C; Kadomatsu M; Nojiri T; Onda H; Bae J; Huang Y; Takamatsu K; Yamashita S; Kangawa K; Tachibana H
    J Biol Chem; 2017 Jun; 292(26):10813-10823. PubMed ID: 28507102
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Widely metastatic atypical pituitary adenoma with mTOR pathway stk11(F298L) mutation treated with everolimus therapy.
    Donovan LE; Arnal AV; Wang SH; Odia Y
    CNS Oncol; 2016 Oct; 5(4):203-9. PubMed ID: 27615706
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of lkb1 and activation of AMPK in PDACs.
    Cheng X; Kim JY; Ghafoory S; Duvaci T; Rafiee R; Theobald J; Alborzinia H; Holenya P; Fredebohm J; Merz KH; Mehrabi A; Hafezi M; Saffari A; Eisenbrand G; Hoheisel JD; Wölfl S
    Mol Oncol; 2016 Jun; 10(6):806-24. PubMed ID: 26887594
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Metformin and pancreatic cancer: Is there a role?
    De Souza A; Khawaja KI; Masud F; Saif MW
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):235-42. PubMed ID: 26740120
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Decreased lkb1 predicts poor prognosis in pancreatic Ductal Adenocarcinoma.
    Yang JY; Jiang SH; Liu DJ; Yang XM; Huo YM; Li J; Hua R; Zhang ZG; Sun YW
    Sci Rep; 2015 May; 5():10575. PubMed ID: 26015068
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Ann Oncol; 2012 Sep; 23(9):2327-2335. PubMed ID: 22377565
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. lkb1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.
    Morton JP; Jamieson NB; Karim SA; Athineos D; Ridgway RA; Nixon C; McKay CJ; Carter R; Brunton VG; Frame MC; Ashworth A; Oien KA; Evans TR; Sansom OJ
    Gastroenterology; 2010 Aug; 139(2):586-97, 597.e1-6. PubMed ID: 20452353
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Peutz-Jeghers syndrome: genetic screening.
    Leggett BA; Young JP; Barker M
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):518-24. PubMed ID: 12934663
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Progress in cancer genetics: lessons from pancreatic cancer.
    Goggins M; Kern SE; Offerhaus JA; Hruban RH
    Ann Oncol; 1999; 10 Suppl 4():4-8. PubMed ID: 10436774
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The molecular basis and clinical aspects of Peutz-Jeghers syndrome.
    Hemminki A
    Cell Mol Life Sci; 1999 May; 55(5):735-50. PubMed ID: 10379360
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.